Thrombospondin-1 (TSP-1), a matricellular protein and one of the first endogenous anti-angiogenic molecules identified, has long been considered a potent modulator of human diseases. While the therapeutic effect of TSP-1 to suppress cancer was inves- 
has been termed matricellular proteins, and it represents an expanding group of molecules that includes over nine subfamilies of proteins that are increasingly recognized as playing important roles in homoeostasis and recently in diseases. 2 As the name implies matricellular proteins function to span the area between the cell surface and the matrix scaffold. Also important to the understanding of these molecules is that they do not impart strength to the matrix themselves, instead they can regulate matrix metabolism to alter the biomechanical properties of the extracellular matrix.
A quintessential and founding member of this group is thrombospondin-1 (TSP-1), a protein first identified in the particulate fraction of thrombin-activated platelets 3 and this fact being incorporated in its name. Like many secreted proteins post-development, TSP-1 is minimally detectable in health but rapidly up-regulated with injury and persists in chronic diseases, being found in the parenchyma as well as fluid compartments including the blood, 4 urine 5 and cerebrospinal fluid. 6 TSP-1 is trimeric, with each monomer about 130-150 kD, but the secreted protein is heavily modified by glycosylation and weighs over 450 kD ( Figure 1 ). 7 Secreted TSP-1 directly transduces signals through binding via discrete domains to cell-surface receptors including but not limited to CD47, CD36 and integrins. 8 Indirectly, TSP-1 regulates cell signalling through binding to other molecules such as enzymes and growth factors. 9, 10 Consequently, the manifold roles of TSP-1 in modulating cell functions are concentration-and cell type-specific. Nonetheless, some trends have emerged. From the perspective of pharmacology, high concentrations of TSP-1 check the cell cycle in primary cells to impede selfrenewal and proliferation 11 and can, at certain concentrations, induce cell death. 12, 13 These effects arise, in part, from the ability of TSP-1 to limit pro-growth signals and several key elements of metabolism. 14 Another essential feature of TSP-1 is its ability to control tissue repair and remodelling in response to injury and stress, a property enhanced by its important function to increase transforming growth factor beta (TGF-beta) activity. 15 In the central nervous system, TSP-1 is expressed and secreted by astrocytes and is a promoter of synapse formation as well as neuronal proliferation and differentiation. 16 During immune activation, TSP-1 has a supportive role and can increase the activation of inflammatory cells including monocytes, 17 dendritic cells, 18 macrophages 19 and T cells. 20 Conversely, in other settings such as during the resolution of inflammation, TSP-1 may act to suppress inflammation. 21, 22 A fundamental and well-established property of TSP-1 is to limit endothelial cell (EC)-mediated angiogenesis by inhibiting the activity of vascular endothelial growth factor (VEGF) 23 and the pleiotropic signals of the gasotransmitter nitric oxide (NO). 24 In this way, TSP-1 adversely impacts angiogenesis and blood flow 25 and modulates blood pressure by limiting NO-mediated vasorelaxation. 26 In this latter capacity, TSP-1 is now recognized to alter cardiovascular responses in general. 25, 27 In the light of its role to retard angiogenesis, TSP-1 is shown to suppress tumour growth and is often found down-regulated in the tumour microenvironment coincident with accelerated tumour invasiveness. 28 Increases in circulating TSP-1 expression have also been found to be positively correlated with patient survival in some cancers. 29, 30 Expectantly, TSP-1-derived drugs have been developed in the interest of inhibiting angiogenesis and treating cancer. 31, 32 However, the effect of TSP-1 in cancer is not simple, and it has been reported that TSP-1 can also support tumour growth and spread. 33 Interest has been growing in TSP-1 as a possible biomarker and an important contributor to human diseases, particularly in age-related and metabolic diseases. 34, 35 At the same time, TSP-1 and several of its cell-surface receptors, notably CD36 and CD47, have and continue to be pursued as therapeutic targets. 36, 37 Renewed appreciation of TSP-1 in the pathophysiology of diseases has encouraged research into the expression of this protein in different cells and body compartments. However, a systematic characterization and quantification of published TSP-1 expression data in diseases, both amount and rate of production, has not been previously approached. Such an analysis is important, and it can provide insight into the sometimes conflicting activity of this molecule and serve to guide therapeutic interventions that target pathways mediated by TSP-1; it is also important for systems biology computational studies of TSP-1. rather than in the tumour cells. 44, 57, 58 In addition, published data of TSP-1 mRNA expressions across various cell lines show a qualitatively similar trend compared with the secretion rates presented in Table 1 . 59 Still, production and secretion rates of TSP-1 would depend on various factors including the density of cultured cells and also the appropriate stimuli which are present in tissue environments in vivo but may not be contained in the culture media; therefore, the differences between cell-specific secretion rates outlined here should be interpreted in both quantitative and qualitative manners.
Further studies and measurements are needed to elucidate the potential correlations between in vitro (summarized in this review) and in vivo TSP-1 production capacities in the different cell types.
| QUANTITATIVE TSP-1 EXPRESSION PROFILES IN PATHOLOGICAL CONDITIONS

| Human cancers
The potential of circulating and tissue TSP-1 protein as diagnostic or prognostic markers for cancers, given its anti-angiogenic and proapoptotic properties, has been studied extensively. Table 2 summarizes the quantitatively measured TSP-1 protein levels in the plasma, serum, platelet and tissue of individuals with various cancer conditions. Most measured values of plasma TSP-1 protein levels are in the range of a few hundred to a few thousand ng/mL, indicating that physiological TSP-1 concentrations are relatively low in the circulation. 86 It should be noted that data on soluble plasma and serum TSP-1 may be confounded by varying degrees of platelet activation that serve as a reservoir of pre-formed TSP-1 in alpha granules during sample acquisition and processing. 42 Nonetheless, it is worth noting that a large portion of the plasma TSP-1 data actually indicate an up-regulation of TSP-1 in patients with cancer compared to normal controls, especially in breast cancer, which might be considered counterintuitive to the well-established anti-angiogenic property of TSP-1. In the case of breast cancer (general disease and not in the context of any specific subtypes), four separate studies have found a consistent, significant increase in plasma or tissue TSP-1 protein in patients with cancer compared to healthy controls. 67, 71, 83, 87 A strong positive correlation between plasma and intratumoural TSP-1 is observed, and patients with lymph node metastasis have significantly higher plasma TSP-1 compared to lymph node-negative patients.
Intratumoural TSP-1 expression is also positively correlated with microvessel density, suggesting a pro-angiogenic role of TSP-1 in breast cancer. 67 The up-regulation of tissue TSP-1 expression in breast cancer is further supported by TSP-1 mRNA and immunohistochemical data. 88, 89 In non-small cell lung cancers, significantly lower plasma and serum levels of TSP-1 have been observed in patients, 75 and higher baseline serum TSP-1 levels are found associated with increased overall survival in patients receiving treatments. 76 In colon cancer, conflicting results of plasma TSP-1 in patients versus controls have been reported. 72, 73 In pancreatic cancer, serum TSP-1 is down-regulated in patients with cancer. 78, 79 In glioblastoma, no significant difference is observed in serum TSP-1 levels in patients compared to healthy subjects, but higher pre-surgery serum TSP-1 is prognostic of longer survival in patients after tumour resection. 80 Overall, these data suggest that the cancerdriven regulation of TSP-1 expression in humans may be highly 
| Cardiovascular diseases
In contrast to cancer, angiogenesis is often impaired and therefore desired in many age-related and cardiovascular diseases, especially in ischaemic vascular diseases such as coronary artery disease (CAD) 99 This may be in part secondary to the known effects of high glucose on TSP-1 production. 100 In terms of disease outcome, strong negative correlations between plasma TSP-1 protein levels and patient survival have been observed for pulmonary hypertension, acute ischaemic stroke and end-stage renal disease, all conditions characterized by vasculopathy. [101] [102] [103] Interestingly, on the other hand, thrombospondin proteins including TSP-1 are involved in the unfolded protein response (also known as the endoplasmic reticulum stress response), and they are found to be induced and exert protective effects following myocardial injury in animal models, which adds another layer of complexity to the functions of the up-regulated TSP-1 in cardiovascular diseases. 104 The cell-surface receptors that TSP-1 interacts with also have important therapeutic value in cancer and cardiovascular diseases. CD36 is a low-affinity receptor which recognizes the type I repeats of TSP-1 Besides diseases, many natural biological processes can also contribute to the endogenous regulation of TSP-1. Preclinical studies in mice have demonstrated age-associated up-regulation of TSP-1 in kidney, 127 heart 128 and skin. 129 The fact that both TSP-1 and CD47
| Correlations between TSP-1 and VEGF
are significantly induced in the skin of aged mice and negatively act on blood flow may imply a deleterious role of TSP-1/CD47 axis in ageing and ageing-related complications. 95 In addition, diabetesinduced up-regulation of TSP-1 may contribute to ageing-related vascular rarefaction in the hearts of leptin-resistant mice, and loss of TSP-1 expression can attenuate this pattern. 130 Exercise is another factor that seems to control TSP-1 dynamics. Confirmed in both mice and humans, TSP-1 expression is greatly increased in skeletal muscles following active training and this is accompanied by an increase in VEGF expression. 131, 132 Interestingly, a delay is observed between TSP-1 induction and VEGF induction (VEGF induction preceding TSP-1), which suggests endogenous feedback mechanisms through timely regulation of pro-and anti-angiogenic factors to sustain adequate but not excessive angiogenesis and blood flow during and after exercise. 133 Gestation status can also affect TSP-1 expression in the uterus, in which TSP-1 expression was shown to increase over the last few weeks before labour and peak during labour, 134 putatively where its role to promote platelet activation by resisting NO-mediated effects on platelets 135 and blood vessels 26 may have beneficial effects to limit haemorrhage.
The inconsistent pattern of TSP-1 expression observed in different types of cancer is reflected in the equally controversial role of tumour TSP-1 expression as a survival predictor. In accordance to its anti-angiogenic property, high tumour expression of TSP-1 is correlated with increased patient survival in colon, 136 lung, 137 bladder, 138 ovarian, 139 cervical 140 and gastric cancer. 109 However, high tumour tissue TSP-1 is also associated with decreased survival in patients with hepatocellular carcinoma, 81 breast cancer 141 and melanoma. 142 Along with the observation that high VEGF in cancer is usually associated with worse prognosis and increased metastasis, 106 it is very likely that certain types of cancer (eg breast cancer) may have developed compensatory mechanisms to counteract the anti-angiogenic pathways activated by TSP-1. 143, 144 Resistance to apoptosis and 
